A Conversation We feel a sense of honor and responsibility when people are interested in the challenges we are tackling at Perfood. Recently, the former minister of health for the state of Schleswig-Holstein, Dr. Heiner Garg stopped in for an informal visit. Dr. Garg spoke with CEO Dominik Burziwoda and spent time in the guts of our operations, where the CGM sensors and therapy kits are carefully put together and sent out to people facing the challenges of type 2 diabetes and migraines. While a visit may seem to many like just a small occurrence in the humdrum of a startup, it is in fact much more. Innovation cannot be sustained and cannot succeed without open and robust conversations. In fact, it may be as important as the science, technology, and product development that must take place to actually change the course of the diseases that affect millions of people, and our economic prosperity. In the case of Dr. Garg, he knows firsthand that effective healthcare begins with a clear and open understanding. In fact, even before he was a health minister and FDP leader in Schleswig-Holstein, he wrote a paper entitled: 📎 ‘The need for care as an object of economic security policy’ ("Pflegebedürftigkeit als Gegenstand ökonomischer Sicherungspolitik"). This focus on the importance of the big picture in healthcare is critical. As a startup, the path to effectively integrating our innovations and products into the healthcare system is not straightforward — and we don’t expect it to be. Healthcare is about people, and as such requires oversight and the contributions of many stakeholders. This is an attitude we fully embrace. When we look at just the challenges around diabetes and the scale of the response needed, we see how much we can contribute to this immense priority. This mission is what drives us. In the case of Dr. Garg, perhaps another reason he was curious about us as a digital therapeutics and DiGA company is that he was at the epicenter of the COVID-19 pandemic response in Schleswig-Holstein. He knows intimately that there needs to be a strong capacity to innovate and, in some instances, do it as quickly as we can think. As Dominik Burziwoda always points out, in the area of prescription digital therapeutics, Germany has a once-in-a-century opportunity to be the definitive leader in this emerging sector. But in pursuing this lofty goal, we know that the most important part of what we have to do is to have open, collaborative, and productive conversations with all stakeholders. We may not always see the problems and solutions in the same way, but with openness and conversation, we are confident we will always find the path forward. So while this was just a short visit from someone who has seen and contributed to addressing some of the biggest health challenges of our time, we see it as a model of what will make German innovation in healthcare a success story — an open conversation. #germany #healthcare #innovation
Perfood’s Post
More Relevant Posts
-
The Future of Health Care: Insights from Eric Palmer at #EvernorthOutcomes Eric Palmer, President and CEO of Evernorth Health Services, recently shared his vision for the future of health care. Key topics included reducing drug prices, the role of biosimilars, and improving patient access through enhanced guidance. These are crucial steps toward a more efficient and equitable system. Watch the full video for more insights: https://lnkd.in/gzCeJEAn #HealthCareInnovation #Biosimilars #MedMind #AccessToCare #PatientOutcomes
-
Country Head and General Manager, Sandoz UK & Ireland, Chair of British Generics Manufacturers Association (BGMA)
As NICE - National Institute for Health and Care Excellence approaches its 25th birthday, it's time to reflect on the role of Health Technology Assessment (HTA) within our ever-evolving healthcare ecosystem. NICE has been recognized globally for its pioneering approach to evidence-based guidance, and it’s rightfully viewed as the gold standard HTA body. However, its focus on new medicines has arguably been too skewed for the duration of its 25-year lifespan. As a society, we all want access to the newest medicines, and it’s right that NICE duly prioritizes their appraisal. But the extent of its prioritization has meant that the population health benefits of generics and biosimilars have often been overlooked. Therefore, at Sandoz UK, we are calling for NICE to establish a default process for reappraising medicines when they lose exclusivity to unlock these benefits. There’s clear precedent: in 2021, NICE reissued guidance for rheumatoid arthritis, finding that the cost-reduction associated with biosimilars meant 25,000 more patients could access treatment. This is demonstrative of the health gain that can be derived from the proactive reassessment of off-patent medicines. Amidst a rapidly evolving healthcare landscape, NICE is embracing transformation and responding to the changing needs of society. It is currently consulting on how it prioritizes guidance, which represents an opportune moment for NICE to look again at the way it assesses the value profile of off-patent medicines. NICE has come a long way in 25 years, and in a further 25 years’ time, it can be a world leader not only in evidence-based guidance, but also in the way it assesses the value offered by medicines throughout their lifecycle – not just at launch. Together, we have the power to drive positive change, ensuring that NICE remains agile, impactful, and a cornerstone of healthcare excellence. #NICE #Healthcare #Transforming #EvidenceBasedMedicine
-
-
We had an insightful panel discussion on "Bridging the Gaps from Diagnosis to Treatment Outcomes." A heartfelt thank you to our esteemed panelists for meaningful and impactful contributions, making this event a remarkable success. Their expertise and dedication to improving healthcare outcomes are truly remarkable. We are grateful for your commitment to excellence and the collaborative spirit you brought to the discussion. The discussions highlighted key Healthcare aspects including the collaborative efforts between MNC’s and Government, the role of Patient Assistance Programs in fostering Treatment Retention, emphasizing Patient Empowerment, Tele counselling, and Patient Advocacy, the growing focus on research outreach to Tier 2 and Tier 3 cities, and the evolving landscape of digital health devices with a spotlight on patient intervention. The discussions held during the event shed light on challenges like self-awareness, Patient adherence. Mr. Anil Matai OPPI India, Mr. Dr. Vikas Gupta Alkem Laboratories Ltd., Ms. Shweta Rai Bayer, Mr. Gautam Khanna Hinduja Hospital, Mr. Vikrant Shrotriya Novo Nordisk, Ms. Farida Hussain, QMS MAS , Mr. Mahesh Makhija, Mr. Mohit Tamhankar, Mrs. Ranjeeta Vinil, Mr. Rajesh Jha, Aristo Pharmaceuticals Pvt. Ltd., Lupin, Ipca Laboratories Limited, SUN PHARMA Sanofi Indian Pharmaceutical Association #HealthcareInnovation #PanelDiscussion #Bridgingthegaps #PharmaConnect #ExpertInsights #PharmaLeaders #HealthcareInsights
-
-
Versatile leader in clinical development operations, building the bridges for wellbeing, between biotech, health tech, clinical researchers, clinicians and patients
#ElevateHealth: the interplay between individuals, healthcare institutions and the healthcare ecosystem. 💭The simple three-layers graphic Dr. Petra Nathan posted tries to structure a complex interplay that is acutely relevant, and we must discuss if we are to overcome some of the constraints in our ability to care for patients and drive for the best health-outcomes. Why this is so, is illustrated in the following example. ✅In a recent client project, Volv Global SA demonstrated that it is possible to predict undiagnosed patients living with Fabry or Pompe disease, so that GPs can triage them for referral and confirmatory diagnosis. A brilliant result, one would think. Because left unchecked, both diseases, for which there are effective treatments, lead to serious complications affecting several organs, and poor outcomes for patients. 🚧However, we soon discovered a barrier in one of the EU countries for which we calibrated these algorithms: under changing regulations, it has become seemingly impossible to generate the evidence package to support a health technology assessment for medical device registration. 🛣A way forward is needed to navigate the regulatory landscape and optimise for the best outcomes at all levels in the system: patients seeking benefit from timely diagnosis; HCPs whose workload needs to remain manageable to provide the right levels of care and an overall healthcare system that remains affordable. 💡This example illustrates that we need to explore and understand the relationship between the layers in the system. Seek the dialogue, reveal the barriers and jointly establish the optimal way forward, to enabling patient journeys that lead to the best outcomes for patients in a sustainable manner. To find out more about the #ElevateHealth project kick-off sessions at the Terrapinn World Orphan Drug Congress Europe in Barcelona in October, see link here: https://lnkd.in/eh4neXJH And follow the #ElevateHealth LinkedIn group here: https://lnkd.in/e9r4j_-s #inTrigue #inClude #aiinnovationinhealth #sustainablehealthcare With Volv Global SA 💭 Christopher Rudolf, Le Vin Chin, Vahid Esmaeili, Heidi Bezzant, Novartis Dr. Petra Nathan, Michael Rebhan, Fondation Ipsen James Levine and many others.
-
-
Partnerships between different stakeholders in the healthcare industry are crucial for driving healthcare transformation. Stakeholders can include diverse groups – not just payors, governments and providers, but also pharma companies, academic centers and private practices. But by working together, these stakeholders can address challenges such as treating complex diseases, reducing costs, and increasing efficiency, all while improving patient outcomes. If you can figure out how to work together, everybody comes at it from a unique angle, each stakeholder uses different tools…collaboration is something that is unique. It doesn’t happen often where you have all these different players all trying to work together, with one common agenda that ultimately benefits the patients.” https://lnkd.in/eKQ-424e
Partnerships are key to driving digital healthcare transformation in US, say experts - Pharmaceutical Technology
pharmaceutical-technology.com
-
During an insightful panel discussion organized by Saarathi Healthcare, Anil Matai, DG of OPPI India, emphasized the long-term solutions to India’s healthcare challenges. He elaborated on the need to critically evaluate the systems in place. #BharatKeLiye
We had an insightful panel discussion on "Bridging the Gaps from Diagnosis to Treatment Outcomes." A heartfelt thank you to our esteemed panelists for meaningful and impactful contributions, making this event a remarkable success. Their expertise and dedication to improving healthcare outcomes are truly remarkable. We are grateful for your commitment to excellence and the collaborative spirit you brought to the discussion. The discussions highlighted key Healthcare aspects including the collaborative efforts between MNC’s and Government, the role of Patient Assistance Programs in fostering Treatment Retention, emphasizing Patient Empowerment, Tele counselling, and Patient Advocacy, the growing focus on research outreach to Tier 2 and Tier 3 cities, and the evolving landscape of digital health devices with a spotlight on patient intervention. The discussions held during the event shed light on challenges like self-awareness, Patient adherence. Mr. Anil Matai OPPI India, Mr. Dr. Vikas Gupta Alkem Laboratories Ltd., Ms. Shweta Rai Bayer, Mr. Gautam Khanna Hinduja Hospital, Mr. Vikrant Shrotriya Novo Nordisk, Ms. Farida Hussain, QMS MAS , Mr. Mahesh Makhija, Mr. Mohit Tamhankar, Mrs. Ranjeeta Vinil, Mr. Rajesh Jha, Aristo Pharmaceuticals Pvt. Ltd., Lupin, Ipca Laboratories Limited, SUN PHARMA Sanofi Indian Pharmaceutical Association #HealthcareInnovation #PanelDiscussion #Bridgingthegaps #PharmaConnect #ExpertInsights #PharmaLeaders #HealthcareInsights
-
-
Expert in guiding entrepreneurs to raise up to $5M through superior investment crowdfunding strategies | Empowering investors in innovative startups to look at equity crowdfunding as the next big thing | Startup mentor
The financial impact of rare diseases on the healthcare system is staggering. It’s a call for urgent reform. (h/t ARK Investment Management LLC) With costs skyrocketing, we need to act now. For patients with rare diseases, the average annual costs are alarming: 1. $8,000 for prescription medicine. 2. $36,000 for non-pharmaceutical health services. This adds up to a total annual medical cost of $400 billion. Additionally, the cost of life years lost is estimated at $240 billion. These numbers highlight a critical need for systemic reforms. The financial burden is immense. Patients with rare diseases face a 26% reduction in lifespan, adjusted for quality-of-life factors. This is not just about numbers; it’s about real lives affected by inadequate healthcare strategies. We need policy interventions. Innovations in treatment approaches are essential. The healthcare system must address both clinical and supportive care needs. Stakeholders across the healthcare spectrum need to engage in this dialogue. Policymakers, researchers, advocacy groups, and pharmaceutical companies all have a role to play. By understanding the economic costs and patient outcomes, we can better manage resources and funding priorities. Effective treatments and support systems are crucial. We must enhance the lives of those affected by rare diseases. A more equitable and sustainable healthcare framework is possible, but it requires comprehensive strategies. Act now to reduce the financial and human toll of rare diseases. ♻️ Repost this if you agree. PS: If you're still on the fence with investment crowdfunding, let me take you by the hand here: [ https://lnkd.in/ejgzhQQa ] 01. Scroll to the top. 02. Click "Ready to invest? GO HERE!" 03. Follow Yvan De Munck to never miss a post. 04. Follow RegCF Rocket on Spotify. 05. Follow RegCF Rocket on Instagram.
-
-
Our #rwe now touches a huge portion of care in America. From large health systems to ambulatory specialty networks our data truly represents care delivery. How can access to research grade clinical data help you with your 2025 objectives? How can access to billions of clinical notes power your patient focused AI use cases? Reach out to myself or Sean Hill and let's talk.
Looking forward to attending the #DIA RWE conference in Philadelphia October 24th-25th. It's a great chance to delve into the latest advancements and innovative applications of #RWE, especially what we are working on here at OMNY Health. Let me know if interested in stopping by our booth!
Real-World Evidence Conference
diaglobal.org
-
At BMS, we are passionate about improving patients' access to medicines and our seminar on "How to modernize the Swedish introduction system" at Almedalen (which external commentators called "among the best events of the week") had some key-takeaway messages that I wanted to highlight namely: - The medical needs of the regions must be assessed better and regional collaboration strengthened to improve the introduction of innovation - The government must take greater responsibility for precision medicines and orphan drugs - Regions need to be encouraged (& resourced appropriately) to participate in “trepartsöverläggningar”; TLV will support this process I share some of my reflections in the video below and if you're interested in the details, read the report here : https://lnkd.in/eJvinXUB Together with all of the actors interested in alleviating patient burden, we believe we can make a difference and contribute to the long term health of Swedish society in a sustainable way. #BMSSverige #BMS_Employee #Almedalen2024 #läkemedel #hälsoochsjukvård #innovation #framtidensvård
-
Professor at Johns Hopkins Carey Business School and Johns Hopkins Bloomberg School of Public Health
My comments AIS Health: GoodRx to Offer Humira Biosimilar, but Can Patients Afford Cash Price? GoodRx, Inc. has dipped its toes into the booming Humira (adalimumab) biosimilar market with the help of Boehringer Ingelheim (BI), which will offer patients its Cyltezo (adalimumab-adbm) interchangeable adalimumab biosimilar direct to patients through GoodRx. "The PBMs all have their own [preferred] biosimilar for Humira," Bai tells AIS Health. "Other competing biosimilar makers have their entrance blocked with those PBMs — PBMs will prioritize their own biosimilar. These three PBMs are so powerful, and have such a big market share,” she says, referring to UnitedHealth Group's Optum Rx, The Cigna Group's Express Scripts, and CVS Health Corp.'s Caremark. “That's really pushing the biosimilar makers to seek alternative outlets to access the market." "GoodRx has already established its own channel to reach patients," Bai says, "so it's a natural move." Bai says there's a worthwhile comparison between LillyDirect, Eli Lilly & Co.'s direct-to-consumer GLP-1 prescribing and sales service, and the new GoodRx-BI joint venture. Since some health plans are loath to include GLP-1s in their formularies, Lilly had a strong incentive to stand up its own channel. "It's like water," Bai says. "If you stop the water from fl owing in one direction,it will find another outlet." The Johns Hopkins University - Carey Business School Johns Hopkins Bloomberg School of Public Health https://lnkd.in/eVYAHqtF
